# AbbVie Inc. (ABBV) FY2026 Q1 P&L / Income Statement

- Company: AbbVie Inc. (ABBV)
- Period: 2026-01-01 to 2026-03-31
- Filing: Q1 FY2026 10-Q, filed 2026-05-08, accession number 0001551152-26-000017
- Page: https://plicit.ai/financials/abbv/fy2026-q1-income-statement
- Chart image: https://plicit.ai/charts/abbv-fy2026-q1-income-statement-sankey.png

## Chart details: Revenue by Key Product Portfolio by Product and Service

Income statement for 2026-01-01 through 2026-03-31. View: Key Product Portfolio by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net revenues**: 15,002,000,000 US dollars
- **Cost of products sold**: 4,218,000,000 US dollars
- **Gross profit (calculated)**: 10,784,000,000 US dollars
- **Operating expenses (calculated)**: 6,794,000,000 US dollars
- **Operating earnings**: 3,990,000,000 US dollars
- **Other income (expense), net (calculated)**: negative 2,951,000,000 US dollars
- **Earnings before income tax expense**: 1,039,000,000 US dollars
- **Income tax expense**: 342,000,000 US dollars
- **Net earnings**: 697,000,000 US dollars
- **Aesthetics - Botox Cosmetic**: 668,000,000 US dollars
- **Aesthetics - Juvederm Collection**: 232,000,000 US dollars
- **Aesthetics - Other Aesthetics**: 286,000,000 US dollars
- **Immunology - Humira**: 688,000,000 US dollars
- **Immunology - Rinvoq**: 2,119,000,000 US dollars
- **Immunology - Skyrizi**: 4,483,000,000 US dollars
- **Neuroscience - Botox Therapeutic**: 1,009,000,000 US dollars
- **Neuroscience - Other Neuroscience**: 125,000,000 US dollars
- **Neuroscience - Qulipta**: 296,000,000 US dollars
- **Neuroscience - Ubrelvy**: 339,000,000 US dollars
- **Neuroscience - Vraylar**: 905,000,000 US dollars
- **Neuroscience - Vyalev**: 201,000,000 US dollars
- **Oncology - Elahere**: 198,000,000 US dollars
- **Oncology - Epkinly**: 83,000,000 US dollars
- **Oncology - Imbruvica**: 556,000,000 US dollars
- **Oncology - Venclexta**: 770,000,000 US dollars
- **Other Key Products - Linzess**: 283,000,000 US dollars
- **Other Key Products - Mavyret**: 351,000,000 US dollars
- **Undisclosed (calculated)**: 1,410,000,000 US dollars
- **Selling, general and administrative**: 3,578,000,000 US dollars
- **Research and development**: 2,472,000,000 US dollars
- **Acquired IPR&D and milestones**: 744,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to AbbVie Inc.: $695.00 M; to noncontrolling interests: $2.00 M.